MicroRNA manipulation in colorectal cancer cells: from laboratory to clinical application

Muhammad Imran Aslam1,2*, Maleene Patel1,2, Baljit Singh1,2, John Stuart Jameson2 and James Howard Pringle1,2

Abstract

The development of Colorectal Cancer (CRC) follows a sequential progression from adenoma to the carcinoma. Therefore, opportunities exist to interfere with the natural course of disease development and progression. Dysregulation of microRNAs (miRNAs) in cancer cells indirectly results in higher levels of messenger RNA (mRNA) specific to tumour promoter genes or tumour suppressor genes. This narrative review aims to provide a comprehensive review of the literature about the manipulation of oncogenic or tumour suppressor miRNAs in colorectal cancer cells for the purpose of development of anticancer therapies. A literature search identified studies describing manipulation of miRNAs in colorectal cancer cells in vivo and in vitro. Studies were also included to provide an update on the role of miRNAs in CRC development, progression and diagnosis. Strategy based on restoration of silenced miRNAs or inhibition of over expressed miRNAs has opened a new area of research in cancer therapy. In this review article different techniques for miRNA manipulation are reviewed and their utility for colorectal cancer therapy has been discussed in detail. Restoration of normal equilibrium for cancer related miRNAs can result in inhibition of tumour growth, apoptosis, blocking of invasion, angiogenesis and metastasis. Furthermore, drug resistant cancer cells can be turned into drug sensitive cells on alteration of specific miRNAs in cancer cells. MiRNA modulation in cancer cells holds great potential to replace current anticancer therapies. However, further work is needed on tissue specific delivery systems and strategies to avoid side effects.

Keywords: Antisense, CRC, Oligonucleotide, LNA, MicroRNA, miRNA-sponges, miR-mask

Background

Colorectal cancer (CRC) is the third most common neoplasm worldwide. According to the International Agency for Research on Cancer, approximately 1.24 million new cases of CRC were detected worldwide in 2008 [1]. The incidence of CRC is on the rise in developing countries, southern and eastern Europe [2-4]. Contrary to the current trend in Europe, the incidence of CRC in the USA has fallen in the last two decades [5]. The lifetime risk for developing CRC [6] in men is 1 in 16 whereas in women it is 1 in 20 (National Statistics, UK). The development of CRC follows the sequential progression from adenoma to carcinoma [7]. The initial genetic alteration results in adenoma formation in which cells exhibit autonomous growth. During the further course of carcinogenesis, intestinal epithelial cells acquire the characteristics of invasion and potential for metastasis. Therefore opportunities exist to interfere with the natural course of disease development and improve cancer specific survival. Such therapeutic interferences can potentially be chemo preventive for high risk individuals, the early detection of colorectal neoplasia, chemotherapy to down stage the surgically resected or resectable cancers, and therapies for palliation of symptoms in advanced stage cancer. Discovery of microRNAs (miRNAs) and their utility in RNA interference has opened a new era of cancer research and potential of new therapies for cancer treatment. This narrative review aims to provide a comprehensive review of the literature about the manipulation of miRNAs in colorectal cancer cells and tissue for the purpose of development of anticancer therapies. Principles of miRNA manipulation and common methods of modulation in vitro and vivo are discussed in detail for the general understanding of readers.

* Correspondence: mia7@leicester.ac.uk
1 Department of Cancer Studies and Molecular Medicine, University of Leicester, Robert Kilpatrick Clinical Sciences Building, Leicester Royal Infirmary, P O Box 65, Leicester LE2 7GJ, United Kingdom
2 Department of Colorectal Surgery, University Hospitals of Leicester, Leicester General Hospital, Gwendolen Road, Leicester LE5 4PW, United Kingdom

© 2012 Aslam et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
This review also aims to provide the update on the role of miRNAs in CRC development and the diagnostic utility of circulating miRNAs.

Methods
A search was performed using Medline, PubMed and The Cochrane Library databases from 2000 to 2011 to identify articles reporting the role of miRNAs in colorectal cancer development, diagnosis and therapy. The following MeSH search headings were used: ‘microRNA’ and ‘colorectal cancer’. The search was further extended by using the following text words and their combinations: ‘microRNA’, ‘blood’, ‘circulation’, ‘diagnosis’, ‘screening’, ‘therapy’, ‘manipulation’, ‘modulation’, ‘stem cells’ and ‘miRNAs’. The related articles’ function in PubMed was used to broaden the search. All the abstracts, studies and citations found were reviewed. The most recent date of the search was 16 July 2011. Information about colorectal cancer related miRNAs was extracted on the following areas: cancer development & progression; diagnostic utility; manipulation in vitro and vivo; development of therapies. Detailed information was extracted from studies that met the inclusion criteria: Studies conducted on human and non-human cells or tissues; blood-based miRNAs- in colorectal cancers and studies published in the English literature. Because of the lack of randomized controlled trials and the heterogeneous nature of the available data, no attempt was made to perform quantitative meta-analyses. In the absence of standard criteria for the quality assessment of laboratory-based, observational studies on miRNA and heterogeneity of outcome measures included in this narrative review, no quality assessment of included studies was carried out. As the study is only a narrative review, no ethical permission or approval was required.

Results
The literature search identified 48 original scientific studies and review articles in which some or all of the outcomes of interest were reported. 18 additional articles and web-based information sites were selected to provide a general background to miRNA and colorectal neoplasia. 36 additional studies were included to supplement the information in colorectal cancer development, detection of circulating miRNAs, and principles of miRNA therapy, design and delivery. This article provides a comprehensive review of the different approaches for restoration of tumour suppressor miRNAs expression and methods of knocking down the tumour promoter miRNAs in cancer cells. Not all the methodologies of miRNA manipulation have been applied to CRC cells and some have been experimented only on other solid organ cancers. As description and elaboration of these methods might provide an insight to future CRC therapies designed on miRNA manipulations, the authors have included principle studies focussing on mechanisms of such manipulation.

Discussion
MiRNA biogenesis and function
miRNAs are single-stranded, evolutionarily conserved, small (17–25 ribonucleotides) noncoding [8] RNA molecules. MiRNAs function as negative regulators of target genes by directing specific messenger RNA cleavage or translational inhibition through RNA induced silencing complex termed as RISC [9,10]. So far around fourteen hundred mature human miRNAs have been described in the Sanger miRBase version 17 (An international registry and database for miRNAs nomenclature, targets, functions and their implications in different diseases). Figure 1 illustrates the biogenesis and mechanism of action of miRNAs [11-18].

MiRNAs and colorectal cancer carcinogenesis
MiRNAs play an important role in colorectal tumour biology including; oncogenesis; progression; invasion; metastasis and angiogenesis [19-22]. Initiation and progression of colorectal neoplasia results from sequential accumulation of genetic alterations in oncogenic and tumour suppressor genes in colonic epithelium [23]. MiRNAs interfere with these genetic mutations and are involved in different stages of cancer of colorectal neoplasia. Slaby and colleagues summarized the role of different miRNAs in the development of colorectal cancer and emphasized the importance of Adenomatous Polyposis Coli (APC), Tumour Protein 53 (TP53) gene mutations and the WNT signalling Pathway [24]. The initiation of colonic neoplasia is strongly linked to inactivation of the APC gene and activation of the WNT Signalling Pathway. APC inactivation has been found in more than 60% of colonic tumours and such inactivation is associated with up regulation of miR-135a/b in colonic epithelial cells [23,25,26]. Accumulation of any further somatic mutations leads to further dysregulation of miRNAs and activation of additional downstream pathways. For example let-7, miR-18a & miR-143 are strongly linked to KRAS knockdown and activation of the EGFR-MAPK pathway [27-29] whereas miR-21 and miR-126 are associated with augmentation or inactivation of the phosphatidylinositol-3-kinase (PI-3-K) pathway respectively [30,31]. Activation of these downstream pathways results in autonomous tumour cell growth, increased cell survival, and initiation of angiogenesis. Loss of P53 is a critical step in transformation of adenoma to adenocarcinoma as nearly 50–70% of colonic adenocarcinomas are found to be P53 mutant [23]. miR-34a has been identified as a direct downstream target of P53 and the replacement of miR-34a has achieved p53 induced effects of apoptosis and cell cycle arrest [32]. A commonly up regulated miR-17-92 cluster (miR-17, miR-
18a, miR-19a, miR-20a, miR-19b & miR-92a) also drives the progression of adenoma to adenocarcinoma by upregulation of c-myc [33]. Figure 2 summarises the interaction of different miRNAs in signalling pathways for colorectal cancer development and progression. In the KEGG pathway, it shows the interaction of different miRNAs in the formation of adenoma and its progression to adenocarcinoma.
Another cancer pathway- the second serrated neoplasia pathway has recently gained acceptance and is for the most part, APC and TP53 mutation independent. It involves distinct molecular features of somatic BRAF mutation con-
part, APC and TP53 mutation independent. It involves dis-
pathway has recently gained acceptance and is for the most
(CIMP-H) and microsatellite instability (MSI+) associated
find the link of miRNAs associated with this pathway.
emerging and would require further functional studies to
volvement of the miRNAs in the latter pathway is slowly
with mutt homologue 1 (MLH1) methylation [34,35]. In-
leading to either tumour cell proliferation or apoptosis
expression of oncogenes in normal tissue (Figures 3 & 4).
Expression of oncogenes and tumour suppressor genes contrib-
ates to tumour formation by inducing cell proliferation, invasion, angiogenesis and decreased cell death [19]. This has further lead to belief that over expressed miRNAs in tumour cells function by inhibiting different tumour suppressor genes whereas miRNAs that are often found silenced in tumour cells downregulate the expression of oncogenes in normal tissue (Figures 3 & 4).
Amplification, translocation, pleomorphism or mutation in miRNA transcribing genes results in over production of miRNAs. In contrast, mutation, deletion, promoter methylation or any abnormalities in the miRNA biogenesis results in silencing of miRNAs in tumour cells [19]. Table 1

Figure 2 Carcinogenesis of colorectal cancer cells and role of different miRNAs in cancer pathways. In the carcinogenesis of CRC, higher levels of miR-135a & miR-135b are associated with low levels of Adenomatous Polyposis Coli (APC), which in turn leads to activation of the Wnt signalling pathway. Activation of the Wnt signalling pathway is a major tumour initiating event in the colonic epithelium. The low level of APC associated β-catenin degradation complex results in the formation of free cytoplasmic β-catenin that enters the nucleus and activates Wnt-regulated genes through its interaction with TCF (T-cell factor) family transcription factors and concomitant recruitment of coactivators (Survivin, c-Myc and Cyclin D1). As a consequence, there is a lack of apoptosis and increase proliferation of abnormal cells that results in autonomous growth and formation of adenoma. During the course of carcinogenesis, cells in adenoma accumulate few other genetic alterations leading to activation of other signalling pathways e.g. mitogen activated protein kinase (MAPK), Phosphatidylinositol 3-kinases (PI3K) and transforming growth factor-beta (TGFβ) pathways. The let-7 miRNA family, miR-18a and miR-143 are adept at inhibiting the KRAS translation hence switching “off” the MAPK phosphorylation and inactivation of downstream transcription factors c-Myc, c-Fos and c-Jun. Furthermore, a targeted degradation of PTEN and p85β by miR-21 and miR-126 respectively, blocks the PI3K-Akt pathway. These changes drive the early adenoma to a large advanced adenoma. The loss of p53 function is associated with low expression levels of miR-34a family, indicating the role of this miRNA family in the transformation of adenoma to the carcinoma.
summarizes commonly expressed miRNAs in colorectal cancer tissue in comparison to adjacent healthy colonic mucosa [36-49].

Diagnostic utility of circulating miRNAs
Recent studies have shown that tumour-derived miRNAs are present in human body fluids in a remarkably stable form and are protected from endogenous ribonuclease activity. In three different studies researchers have evaluated the suitability of circulating miRNAs as a diagnostic biomarker for CRC [50]. Preliminary studies suggest that CRC derived miRNAs are present in the circulation at detectable levels [51-54] and can accurately distinguish healthy controls from patients with CRC (Table 2). Significantly high sensitivity and specificity for detection of CRC holds promise for the use of circulating miRNAs as a diagnostic biomarker for CRC. Furthermore, the ability of a miRNA based blood assay to detect colonic adenoma can lead to its use in early detection and bowel cancer screening.

Although a small number of studies have identified circulating miRNAs in CRC patients, the clinical utility of this is still questionable. This is due to an overlapping miRNA expression with other solid organ cancers and benign colonic diseases, and variability of individual miRNA expression with tumour site & stage. It is possible that the utility of tumour tissue specific expression-signature/profile may prove more informative and accurate in future clinical studies. Furthermore, the discovery of exosome mediated transport of miRNAs into the circulation, has shifted the focus of miRNA studies towards the isolation of tissue specific circulating exosomes and their contained miRNAs [55].

Principles of miRNA therapy
The fact that miRNAs regulate multiple genes in a molecular pathway, makes them excellent candidates for gene therapy. One of the most appealing properties of miRNAs as therapeutic agents is their ability to target multiple
genes, frequently in the context of a network, making them extremely efficient in regulating distinct biological cell processes relevant to normal and malignant cell homeostasis. The rationale for using miRNAs as anticancer drugs is based on two major principles:

1. MiRNA expression is deregulated in cancer compared with normal tissues
2. Cancer phenotype can be changed by targeting miRNA expression

MiRNA based gene therapy is based on these two principles where manipulation of miRNA expression levels in cancer tissue results in inhibition of tumour growth, apoptosis, blocking of invasion, angiogenesis and metastasis. Restoration of the normal equilibrium for cancer related miRNA expression levels can result in growth retardation and reduced cell viability both in vivo and in vitro experiments. The major obstacle in gene therapy is the safe delivery to specific target tissue without side effects. Rapid degradation by body nucleases and poor cellular uptake owing to the unfavourable chemical structure of synthetic miRNAs have forced researchers to try chemical modifications of synthetic oligonucleotides as well as a more effective means of delivery. To overcome these delivery hurdles, viral and non-viral strategies have been developed. Restoration of tumour-suppressor miRNAs in cancer cells is usually achieved in vitro by using adeno-virus-associated vectors (AAV). These vectors do not integrate into the genome and are eliminated efficiently with minimal toxicity. There are multiple AAV serotypes available, allowing for the efficient targeting of specific tissues including colorectal tissue. The ability of miRNAs to regulate several genes, does create potential problem in terms of side effects. This is a major concern in miRNA therapeutics as such interactions may lead to
toxic phenotypes formation in targeted cells [56]. This has been approached by using nano-particles and tissue specific non viral vectors. However, the concentration dependent knockdown of non specific targets still remains an unresolved issue. This article provides a comprehensive review of the different approaches for restoration of tumour suppressor miRNAs expression and methods of knocking down the tumour promoter miRNAs in cancer cells. Not all the methodologies mentioned in this article have been applied to CRC cells, but all have been investigated as a therapy for other cancers. The description and elaboration of these methods may provide an insight to miRNA therapies in CRC.

### Blocking oncogenic MiRNAs using antisense oligonucleotides

The demonstration that oncogenic miRNAs are upregulated in cancer provided a rationale to investigate the

| Table 1 Summary of dysregulated miRNAs in CRC compared to adjacent normal mucosa |
| --- |
| **Studies** | Downregulated miRNAs in CRC tissue | Upregulated miRNAs in CRC tissue |
| Michael, et al, 2003 [36] | let-7, miR-16, miR-24, miR-26a, miR-102, miR-145, miR-145, miR-200b | miR-16, miR-17-5p, miR-20a, miR-21, miR-29b, miR-141, miR-195, miR-199a |
| Volinia, et al, 2006 [37] | let-7a-1, mir-9-3, mir-23b, mir-138, mir-218 | miR-10a, miR-15b, miR-23a, miR-25, miR-27a, miR-27b, miR-30c, miR-107, miR-125a, miR-191, miR-200c, miR-339 |
| Xi , et al, 2006 [32] | let-7b, let-7g , mir-26a , mir-30a-3p, mir-132, mir-181a, mir-181b, mir-296, mir-320, mir-372 | mir-31, mir-96, mir-135b, mir-183 |
| Bandrés, et al, 2006 [38] | mir-133b, mir-145 | mir-17-5p, mir-21, miR-25, miR-92, miR-93-1, miR-106a |
| Lanza, et al, 2007 [41] | mir-200b, mir-210, mir-224 | miR-19a, miR-20, miR-21, miR-23a, miR-25, miR-27a, miR-27b, miR-29a, miR-30e, miR-746, miR-132, miR-133a, miR-135b, miR-141, miR-147, miR-151, miR-152, miR-182, miR-185 |
| Rossi, et al, 2007 [42] | miR-145 | miR-17-5p, miR-21, miR-30c, miR-106a, miR-107, miR-191, miR-221 |
| Monz, et al, 2008 [43] | miR-101, miR-145, miR-455, miR-484 | miR-20a, miR-92, miR-510, miR-513 |
| Schetter, et al, 2008 [45] | miR-20a, miR-21, miR-106a, miR-181b, miR-203 | miR-17-5p, miR-18a, miR-19a, miR-19b, miR-20a, miR-21, miR-25, miR-20a, miR-29a, miR-31, miR-34a, miR-92-1, miR-93-5, miR-95, miR-106a, miR-106b, miR-173, miR-175, miR-181b, miR-182, miR-183, miR-203, miR-224 |
| Arndt, et al, 2009 [46] | miR-1, miR-10b, miR-30a-3p, miR-30a-5p, miR-30c, miR-125a, miR-133a, miR-139, miR-143, miR-145, miR-195, miR-378*, miR-422a, miR-422b, miR-497 | miR-21, miR-21*, miR-183, miR-92a, miR-17, miR-18a, miR-19a, miR-34a |
| Slattery, et al, 2011 [47] | miR-143, miR-145, miR-192, miR-215 | miR-21, miR-21*, miR-183, miR-92a, miR-17, miR-18a, miR-19a, miR-34a |

*Over expressed or under expressed miRNAs identified by two or more than two studies are underlined whereas the miRNAs with conflicting expression levels in different studies are identified in Bold.

| Table 2 Summary of sensitivity and specificity of different diagnostic circulating miRNAs |
| --- |
| Tissue type | Studies | Participants | Target MiRNAs | Diagnostic accuracy |
| Whole Plasma | Pu, et al, 2010 [51] | CRC (n = 103) | miR-221 | Sensitivity% | Specificity% |
| | Controls (n = 37) | | 86 | 41 |
| Plasma | Cheng , et al, 2011 [52] | CRC I-IV (n = 102) | miR-141 | 66.7 | 80.8 |
| | Controls (n = 48) | | | | |
| RNA | Ng, et al, 2009 [53] | CRC (n = 90) | miR-17-3p | 64 | 70 |
| | Controls (n = 40) | miR-92 | 89 | 70 |
| Huang, et al, 2010 [54] | CRC (n = 100) | miR-29 | 69 | 89.1 |
| | Adenomas* (n = 37) | miR-92a | 62.2* | 84.7* |
| | Controls (n = 59) | | 84 | 71 |

*Adenoma cases.
use of antisense oligonucleotides to block their expression. Antisense oligonucleotides work as competitive inhibitors of miRNAs, presumably by annealing to the mature miRNA guide strand and inducing degradation of mature miRNAs (Figure 5). The stability, and specificity for target miRNAs and the binding affinity of antisense oligonucleotides has been optimised by modifications to the chemical structure of the oligonucleotides [57]. In particular the introduction of 2′-O-methyl or 2′-O-methoxyethyl groups to oligonucleotides enhances resistance to nuclease enzyme and improves the binding affinities to RNA [58]. The silencing of endogenous miRNAs by this novel method has shown to be long lasting, specific and efficient both in vitro [59,60] and in vivo. In CRC cells lines, antimiR based blockage of oncogenic miRNAs (miR-20a, miR-21, miR-31, miR-95, miR-672) has not only shown to reduce cell proliferation, transformation and migration, but it has resulted in enhanced sensitivity to chemotherapy agents [61-66]. This strategy of sensitizing the chemotherapy resistant tumour cells with alteration of miRNA expression in tumour cells may result in improved response to traditional chemotherapy agents. Table 3 summarizes the studies manipulating the oncogenic miRNAs in colorectal cell lines.

**Blocking oncogenic MiRNAs using locked nucleic acid (LNA) Constructs**

LNA construct based anti-miR therapeutic strategy has been extensively explored by researchers studying the miRNA based antiviral therapy for chronic hepatitis-C [66]. LNA nucleosides are a class of nucleic acid analogues in which the ribose ring is ‘locked’ by a methylene bridge connecting the 2′-O atom and the 4′-C atom. By locking the molecule with the methylene bridge, LNA oligonucleotides display unprecedented hybridization...
affinity towards complementary single-stranded RNA and complementary single-stranded or double-stranded DNA [68]. In addition, they display excellent mismatch discrimination and high aqueous solubility. So-called ’LNA anti-miR’ constructs has been used successfully by Valeri and colleagues [67] to knock down miR-21 in colon adenocarcinoma cell lines.

Blocking oncogenic MiRNAs using MiRNA sponge constructs
miRNA sponges based techniques to manipulate oncogenic miRNAs is still in its infancy and has not been studied in detail in CRC cells. miRNA sponges are transcripts that contain multiple tandem-binding sites to a miRNA of interest and are transcribed from mammalian expression vectors. Ebert and colleagues recently reported the use of miRNA sponges in mammalian cells [69]. The authors reasoned that miRNA target sequences expressed at high levels could compete with bona fide targets in a cell for miRNA binding (Figure 5). To increase the affinity of these decoy transcripts, the researchers introduced not only multiple miRNA binding sites, but also a bulge at the position normally cleaved by argonaute 2, therefore facilitating the stable association of miRNA sponges with ribonucleoprotein complexes loaded with the corresponding miRNA. Using these constructs, repression of miRNA targets was observed and proved effective in vitro silencing of miRNAs [69]. Theses effects were comparable with those obtained with 2’-O-methyl-modified oligonucleotides or LNA antisense oligonucleotides. Furthermore, sponges that contained only the heptameric seed were shown to effectively repress an entire miRNA family that shares by definition the same seed sequence [69].

Blocking oncogenic MiRNAs using MiRNA masking antisense oligonucleotides
MiRNA masking effect strategy is designed to target single signalling cancer pathways. miR-mask (miRNA-masking antisense oligonucleotides) technology has been developed by Xiao and colleagues [70]. In contrast to miRNA sponges, miR-masks consist of single-stranded 2’-O-methyl-modified antisense oligonucleotides that are fully complementary to predicted miRNA binding sites in the 3’ UTR of the target mRNA [70]. In this way, the miR-mask covers up the miRNA-binding site to hide its target mRNA (Figure 5), thereby its effects are gene specific. This technology has been applied successfully in a zebrafish model to prevent the repressive actions of miR-430 in the transforming growth factor-β signalling pathway [71]. Although unwanted effects or off-target effects can be dramatically reduced with this approach, this may be a disadvantage for cancer therapy in which the targeting of multiple pathways may be desirable.

Blocking oncogenic MiRNAs using inhibitors of oncogenic pathways
Several drugs may have the ability to modulate the expression of miRNAs by targeting signalling pathways that ultimately converge on the activation of transcription factors which in turn regulate miRNA encoding genes. Furthermore, it is possible to modulate the machinery that contributes to miRNA maturation and degradation processes. The identification of these compounds, however, is not straightforward and requires efficient screening of chemical libraries. Recently, Gumireddy and colleagues identified a method to screen for small-molecule inhibitors of miRNAs [72]. As a proof of concept for this

| miRNA   | Cell line | Target | Method     | Reported effects of miRNA manipulation                                      | References                               |
|---------|-----------|--------|------------|-------------------------------------------------------------------------------|------------------------------------------|
| miR-20a | SW480     | BNIP2  | anti-miR-20a| Increased sensitivity to fluorouracil, oxaliplatin, and teniposide             | Chai, et al, 2011 [61]                   |
|         | SW620     |        |            |                                                                               |                                          |
| miR-21  | RKO       | Pdcd4  | anti-miR-21| Reduced intravasation and distal metastasis                                  | Asangani, et al, 2008 [62]              |
| miR-31  | HCT-116   |        | anti-miR-31| Reduced migration and increased invasion                                      | Wang, et al, 2010 [63]                  |
|         |           | SNX1   | anti–miR-95| Reduced proliferation only with combined 5-FU                                 | Huang, et al, 2011 [64]                 |
| miR-95  | HCT-116 LoVo | EGFR |            | Reduces cell proliferation                                                   |                                          |
| miR-675 | CaCO2 HCT116 HT-29 SW480 | RB | anti-miR-675| Reduced cell growth and colony transformation                               | Tsang, et al, 2010 [65]                |

Locked nucleic acid (LNA)

| miRNA   | Cell line | Target | Method     | Reported effects of miRNA manipulation                                      | References                               |
|---------|-----------|--------|------------|-------------------------------------------------------------------------------|------------------------------------------|
| miR-21  | SW480     | hMSH2  hMSH6 | LNA anti-miR-21| Increased sensitivity to 5-FU                                                  | Valeri, et al, 2010 [67]               |
|         | HCT-116   |        |            |                                                                               |                                          |

http://www.translational-medicine.com/content/10/1/128
approach, the investigators selected the frequently studied and up-regulated miRNA, miR-21. Complementary sequences to miR-21 were cloned into a luciferase reporter gene, which was then used as a sensor to detect the presence of specific mature miRNA molecules. The construct was transfected into HeLa cells, which express high miR-21 levels, resulting in low luciferase activity. Subsequently, a primary screen of more than several small-molecule compounds was done and an initial hit compound, diazobenzene 1, produced a 250% increase in the intensity of the luciferase signal relative to the untreated cells [72]. Additional characterization showed that this compound affects the transcription of miR-21. This strategy could be applied to the screening of small molecules as inhibitors for other distinct oncogenic miRNAs. These could be used with conventional cancer therapeutics to develop novel combined approaches for cancer treatment.

**Restoration of tumour-suppressor miRNAs**

The loss or downregulation of a tumour-suppressor miRNA could be overcome by introducing synthetic oligonucleotides i.e. mature miRNA mimics, miRNA precursors or pre-miRNA mimics into the CRC cells (Figure 6). Introduction of synthetic miRNAs with tumour-suppressor function in cancer cells have been shown to induce cell death and block cellular proliferation, transformation, invasion and migration in several studies as summarized in Table 4. The altered expression of tumour suppressor miRNAs have been studied in the context of cancer-associated transcription factors. p53 mutations have been found in 40–50% of CRCs. The p53 protein is a transcription factor that regulates multiple cellular processes in CRC development, either by regulating mRNA directly or by regulating miRNA indirectly. The absence of p53 mutations in adenomas suggests that loss of p53 is a critical step in progression of adenoma to carcinoma [73,74]. In addition, the miR-34 family has been strongly linked to p53 and loss of p53 has been linked to reduced levels of miR-34 in cancer cells. miR-34a restoration studies [75,76] have clearly demonstrated reduced cell survival, invasion and migration in CRC cell lines. In addition to a link with the p53 pathway, miR-34a encoding genes on their own have been identified as targets for the mutational or epigenetic inactivation in different cancers. Interestingly, miR-34a resides on the chromosomal locus 1p36, which has been proposed to harbor a tumor suppressor gene because it displays homozygous deletions in neuroblastoma and in other tumor types [77]. An unbiased screen for genes with tumor suppressive function on 1p36 also revealed miR-34a as a candidate tumor suppressor gene [78]. Therefore miR-34 targeted gene therapies hold a prime importance in the designing therapies for chemoprevention and to halt the tumour progression. miR-143 is another tumour suppressor miRNA, significantly downregulated in CRC tissues (Table 1). The most significant study in this respect is restoration of miR-143 with miR-143 precursor resulting in reduced proliferation in SW480 colorectal cell lines and tumour suppression on xenografted tumors of DLD-1 human CRC cells [79,80]. Restoration of tumour suppressor miRNA by intravenous injection in mouse with liver cancer resulted in the suppression of tumorigenicity by reduced tumour growth and enhanced tumour apoptosis without signs of toxicity. This illustrates that tumour suppressor miRNA restoration strategy based gene therapy, if delivered efficiently to specific tissues may prove vital in future cancer treatments.

**Modulation of miRNA processing**

Alterations in miRNA processing machinery have also been implicated in cancer development and modulation of this machinery in part or in general can potentially lead to the discovery of new anticancer therapies. Researchers have investigated the global repression of miRNA maturation process in cells and have identified that the abrogation of miRNA processing pathway promotes the cellular transformation and tumorigenesis [91]. The inhibition of Dicer1 activity on its own has also been associated with cancer development, invasion and lymph node metastasis [91-94]. Therefore, speeding up the miRNA processing globally or by replacement of Dicer1 in cancer cells can alter their progression and invasive potential. However, the effects of alterations in miRNA biogenesis pathway have found to vary for different tumour types [92,93] and therapeutic strategy will vary dependent on the response for inhibition or acceleration of miRNA processing.

**Cancer stem cell directed miRNA therapy**

Cancer stem cells or tumor-initiating cells have recently gained enormous attention. According to this hypothesis a subpopulation of cancer cells possesses unique characteristics of self renewal and multipotent differentiation; fundamental characteristics of embryonic and somatic stem cells [95]. As cancer stem cells or tumor-initiating cells are highly resistant to conventional chemotherapy and radiotherapy [96,97] there is further need for stem cell targeted therapy. Accumulating evidence indicates that miRNAs play functional roles in normal and cancer stem cell maintenance and differentiation. MiRNA expression signatures for differentiated cells are distinctly different from embryonic and somatic stem cells [98,99]. However, miRNA expressions in cancer stem cells have significant similarities with embryonic and somatic stem cells. Monzo and colleagues studied the common miRNAs for CRC and embryonic tissue and suggested that the miR-17-92 cluster and its target, E2F1, exhibit a
similar pattern of expression in human colon development and colonic carcinogenesis [43]. Further studies dealing with miRNA biogenesis and stem cells; have suggested that mutation of the key proteins in miRNA biogenesis pathway fail to maintain the self-renewal and differentiation capacities [99-102]. Recent studies have demonstrated the role of let-7 in self renewal, differentiation and regulation of progenitor maintenance. Low expression of let-7 in cancer stem cells and restoration of stem cell related miRNAs expression level in cancer cells might prove pivotal in treating cancers by modulating cancer stem cells.

Conclusions

In summary, there is strong evidence that miRNAs play a significant role in CRC development and progression. There is emerging evidence that miRNAs interact with different cancer signalling pathways and control cellular homeostasis. Changes in miRNAs expression levels results in alteration of this homeostasis and significantly contribute in cancer development and progression. Cancer specific miRNAs are detectable in body fluids and can potentially be used as novel biomarkers for CRC detection and prediction of cancer specific survival. MiRNAs influence oncogenic potential and therefore strategies to manipulate oncogenic or tumour suppressor miRNAs can successfully halt tumour progression. Furthermore, miRNA manipulation strategies can potentially be used as an adjuvant to other forms of anticancer therapies as miRNA manipulation can be used to sensitize drug resistant tumours. Finally, stem cell directed miRNA based therapies can be used to control stemness and latency of cancer stem cells in order to prevent the recurrence of tumour. However, miRNA based gene therapy is still in its infancy, but does hold great potential to replace current anticancer therapies.
therapies. Further work is needed on an efficient, tissue specific delivery system and strategies to avoid side effects.

Competing interest
The authors declare that they have no competing interests.

Authors’ contribution
MIA: literature search, review of studies, critical analysis of studies, layout of manuscript, design of figures and tables. MP: literature search, review of studies, critical analysis of studies. JHP: critical review of manuscript and analysis of the quality of manuscript. BS: reviewed the quality of manuscript. JSJ: Review of quality, structure and design of manuscript. All authors read and approved the manuscript.

Table 4 Summary of studies involving the restoration of silenced miRNAs in CRC cell lines

| miRNAs    | Cell Line | Target         | Method                  | Reported effects of miRNA manipulation | References                        |
|-----------|-----------|----------------|-------------------------|----------------------------------------|-----------------------------------|
| let-7a-1  | DLD-1     | Ras            | let-7a-1 precursor      | Reduced cell viability, cell growth and colony formation | Akao, et al, 2006 [27] |
|           | SW480     | c-myc          |                         |                                        |                                   |
| miR-34a   | DLD-1     | Sirt1          | miR-34a mimic           | Reduced cell growth                    | Akao, et al, 2011 [75] |
|           |           | E2F3           |                         | Enhanced sensitivity to S-FU           |                                   |
| miR-34a   | Rko       | Axl            | pre-miR-34a             | Reduced migration & invasion           | Mudduluru, et al, 2011 [76] |
| miR-133b  | SW-620    | HT-29 tyrosine kinase MET | miR-133b precursor | Reduces cell proliferation Increased apoptosis | Hu, et al, 2010 [81] |
| miR-135a/b| CLY       | CM-1 cytotoxicity | miR-135a, miR-135b mimics | Increased sensitivity to anticancer agent | Li, et al, 2011 [82] |
|           | HT-29     |                |                         |                                        |                                   |
| miR-137   | SW1116,   | Cdc42          | miR-137 mimic           | Reduces cell proliferation, Cell cycle arrest | Liu, et al, 2011 [83] |
|           | Lovo, Colo320 |                |                         | Inhibition of invasion                |                                   |
| miR-143   | SW480,    | DNMT3A         | miR-143 precursor      | Reduces cell proliferation             | Ng, et al, 2009 [79] |
|           | 228       |                |                         |                                        |                                   |
| miR-143   | DLD-1     | miR-143 precursor | tumor-suppressive effect on xenografted tumors of DLD-1 human CRC cells | Nakagawa, et al, 2010 [80] |
| miR-145   | LS174T    | FLI1           | miR-145 precursor      | Reduces cell proliferation and colony formation | Zhang, et al, 2011 [84] |
|           | SW620     | HCT116         |                         |                                        |                                   |
| miR145    | HCT116    | IRS-1          | ds-oligos miR145       | Reduces cell proliferation              | Shi, et al, 2007 [85] |
|           | KO        |                |                         |                                        |                                   |
| miR-185   | SW1116    | RhoA Cdc42     | hsa-miR-185 mimic      | Cell cycle arrest & growth suppression | Liu, et al, 2010 [86] |
| miR-192   | Rko, LoVo, DLD1, SW620 | TYMS | Pre-miR-192 | Reduces cell proliferation | Boni, et al, 2010 [87] |
| miR-195   | HT29 and LoVo | Bcl-2          | miR-195 mimic          | Reduces cellular viability Increased apoptosis | Liu, et al, 2010 [88] |
|           |           |                |                         | Reduced colony formation              |                                   |
| miR-196a  | SW480     | HoxA7, HoxB8, HoxC8 HoxD8 | miR-196a mimics | Reduced migration, invasion Increased cellular adhesion | Schimanski, et al, 2009 [89] |
|           |           |                |                         | Increased sensitivity to platin derived anticancer agents |                                   |
| miR-199a  | Rko       | Axl            | pre-miR-199a            | Reduced migration, invasion           | Mudduluru, et al, 2011 [76] |
| miR 200c  | CLY       | CM-1 cytotoxicity | miR 200c mimics | Low chemosensitivity with high miR-200c | Li, et al, [82] |
|           | HT-29     |                |                         |                                        |                                   |
| miR-215   | Rko, LoVo, DLD1, SW620 | TYMS | pre-miR-215 | Reduces cell proliferation | Boni, et al, 2010 [87] |
| miR-491   | DLD-1     | Bcl-XL         | miR-491 precursor      | Reduces cell proliferation Increased apoptosis | Nakano, et al, 2010 [90] |
5. Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review, 1975–2008, National Cancer Institute. http://seer.cancer.gov/sr/1975_2008/.
6. Bray F, Atkin W. International cancer patterns in men: geographical and temporal variations in cancer risk and the role of gender. JNMHG 2004, 11:36–46.
7. Vogelstein B, Fearon ER, Hamilton SR, et al. Genetic alterations during colorectal-tumor development. N Engl J Med 1988, 319:525–532.
8. Lee RC, Feinbaum RL, The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 1993, 75:843–854.
9. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004, 116(2):281–297.
10. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell 2009, 136:215–233.
11. Lee Y, Ahn C, Han J, et al. The nuclear RNAse III Drosha initiates microRNA processing. Nature 2003, 425:415–419.
12. Bohnsack MT, Czaplinski K, Gorlich D. Exportin 5 is a RanGTP-dependent dsRNA-binding protein that mediates nuclear export of pre-miRNAs. RNA 2004, 10:185–191.
13. Thimmaiah P, et al. TRBP recruits the Dicer complex to Ago2 for microRNA processing and gene silencing. Nature 2005, 436:740–744.
14. Hammond S, Bernstein E, Beach D, et al. An RNA-directed nuclease mediates post-transcriptional gene silencing in Drosophila cells. Nature 2000, 404:293–299.
15. Friedman RS, Farh KK, Burge CB. Most mammalian miRNAs are conserved targets of microRNAs. Genome Res 2009, 19:102–105.
16. Orom UA, Nielsen FN, Lund AH. MicroRNA-10a binds the SUTR of ribosomal protein mRNAs and enhances their translation. Mol Cell 2008, 4:460–471.
17. Eirin A, et al. miR-328 functions as a RNA decoy to modulate hnrNRP E2 regulation of miRNA translation in leukemia blasts. Cell 2010, 140:652–665.
18. Khraiwesh B, et al. Transcriptional control of gene expression by microRNAs. Cell 2003, 116:412–122.
19. Esquela-Kerscher A, Slack FJ. miR-328 functions as an RNA decoy to modulate hnRNP E2 expression. Proc Natl Acad Sci U S A 2006, 103(17):711–715.
20. Friedman RS, Farh KK, Burge CB. Many mammalian mRNAs are conserved targets of microRNAs. Genome Res 2009, 19:102–105.
21.webscience.com content/10/1/128
22. Lee DY, Deng Z, Wang CH, et al. The nuclear RNAse III Drosha initiates microRNA processing. Nature 2003, 425:415–419.
23. Bohnsack MT, Czaplinski K, Gorlich D. Exportin 5 is a RanGTP-dependent dsRNA-binding protein that mediates nuclear export of pre-miRNAs. RNA 2004, 10:185–191.
24. Lee Y, Ahn C, Han J, et al. The nuclear RNAse III Drosha initiates microRNA processing. Nature 2003, 425:415–419.
25. Friedman RS, Farh KK, Burge CB. Most mammalian miRNAs are conserved targets of microRNAs. Genome Res 2009, 19:102–105.
26. Orom UA, Nielsen FN, Lund AH. MicroRNA-10a binds the SUTR of ribosomal protein mRNAs and enhances their translation. Mol Cell 2008, 4:460–471.
27. Eirin A, et al. miR-328 functions as a RNA decoy to modulate hnrNRP E2 regulation of miRNA translation in leukemia blasts. Cell 2010, 140:652–665.
28. Friedman RS, Farh KK, Burge CB. Many mammalian mRNAs are conserved targets of microRNAs. Genome Res 2009, 19:102–105.
29. Bohnsack MT, Czaplinski K, Gorlich D. Exportin 5 is a RanGTP-dependent dsRNA-binding protein that mediates nuclear export of pre-miRNAs. RNA 2004, 10:185–191.
30. Lee Y, Ahn C, Han J, et al. The nuclear RNAse III Drosha initiates microRNA processing. Nature 2003, 425:415–419.
31. Bohnsack MT, Czaplinski K, Gorlich D. Exportin 5 is a RanGTP-dependent dsRNA-binding protein that mediates nuclear export of pre-miRNAs. RNA 2004, 10:185–191.
32. Lee Y, Ahn C, Han J, et al. The nuclear RNAse III Drosha initiates microRNA processing. Nature 2003, 425:415–419.
33. Bohnsack MT, Czaplinski K, Gorlich D. Exportin 5 is a RanGTP-dependent dsRNA-binding protein that mediates nuclear export of pre-miRNAs. RNA 2004, 10:185–191.
34. Lee Y, Ahn C, Han J, et al. The nuclear RNAse III Drosha initiates microRNA processing. Nature 2003, 425:415–419.
35. Friedman RS, Farh KK, Burge CB. Many mammalian mRNAs are conserved targets of microRNAs. Genome Res 2009, 19:102–105.
36. Orom UA, Nielsen FN, Lund AH. MicroRNA-10a binds the SUTR of ribosomal protein mRNAs and enhances their translation. Mol Cell 2008, 4:460–471.
37. Eirin A, et al. miR-328 functions as a RNA decoy to modulate hnrNRP E2 regulation of miRNA translation in leukemia blasts. Cell 2010, 140:652–665.
38. Friedman RS, Farh KK, Burge CB. Many mammalian mRNAs are conserved targets of microRNAs. Genome Res 2009, 19:102–105.
39. Bohnsack MT, Czaplinski K, Gorlich D. Exportin 5 is a RanGTP-dependent dsRNA-binding protein that mediates nuclear export of pre-miRNAs. RNA 2004, 10:185–191.
40. Lee Y, Ahn C, Han J, et al. The nuclear RNAse III Drosha initiates microRNA processing. Nature 2003, 425:415–419.
41. Bohnsack MT, Czaplinski K, Gorlich D. Exportin 5 is a RanGTP-dependent dsRNA-binding protein that mediates nuclear export of pre-miRNAs. RNA 2004, 10:185–191.
42. Lee Y, Ahn C, Han J, et al. The nuclear RNAse III Drosha initiates microRNA processing. Nature 2003, 425:415–419.
Locked nucleic acids: promising nucleic acid mimics. 2008, Proc Natl Acad Sci U S A 105(18):7040–7045.

Locked nucleic acids: do they disrupt the duplex ability of small RNAs in mammalian cells. 2006, Nat Methods 3(10):765–769.

Locked nucleic acids: novel approaches for gene-specific silencing. 2007, Bioorg Med Chem 15(4):1250–1261.

Locked nucleic acids: promising nucleic acid mimics: potential applications in anticancer therapy. 2008, J Mol Biol 378(5):1155–1173.

Locked nucleic acids: anti-miRNA oligonucleotides (AMOs): a new class of therapeutic agents for cancer. 2007, J Med Chem 50(20):5111–5118.

Locked nucleic acids: putative tumor suppressor miR-145 inhibits colon cancer cell growth by targeting oncogene Friend leukemia virus integration 1 gene. Cancer 2011, 117(1):86–95.

Locked nucleic acids: siRNA analogs: alternative designs for the silencing of small RNAs. 2007, J Control Release 122(1):12–25.

Locked nucleic acids: siRNA analogs: alternative designs for the silencing of small RNAs. 2007, J Control Release 122(1):12–25.

Locked nucleic acids: siRNA analogs: alternative designs for the silencing of small RNAs. 2007, J Control Release 122(1):12–25.

Locked nucleic acids: siRNA analogs: alternative designs for the silencing of small RNAs. 2007, J Control Release 122(1):12–25.

Locked nucleic acids: siRNA analogs: alternative designs for the silencing of small RNAs. 2007, J Control Release 122(1):12–25.

Locked nucleic acids: siRNA analogs: alternative designs for the silencing of small RNAs. 2007, J Control Release 122(1):12–25.

Locked nucleic acids: siRNA analogs: alternative designs for the silencing of small RNAs. 2007, J Control Release 122(1):12–25.

Locked nucleic acids: siRNA analogs: alternative designs for the silencing of small RNAs. 2007, J Control Release 122(1):12–25.

Locked nucleic acids: siRNA analogs: alternative designs for the silencing of small RNAs. 2007, J Control Release 122(1):12–25.

Locked nucleic acids: siRNA analogs: alternative designs for the silencing of small RNAs. 2007, J Control Release 122(1):12–25.